29
Aug

Disappointing sales of ThromboGenics’ only marketed product, Jetrea, have taken their toll on the company’s profits this year. To get back in the black, the Belgian company now says it’s spinning out its cancer R&D activities to focus on the struggling eye drug.

…read more

Source: ThromboGenics spins out cancer R&D, scales down staff amid lackluster Jetrea sales

    

0 No comments